Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elif A Oral

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Clinical Endocrinology|November 22, 2015
Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophyJean L Chan, Joy Koda, Joseph S Heilig, et al.
Frontiers in Endocrinology|June 5, 2025
A real-world pharmacovigilance assessment and literature review of lymphoma development in lipodystrophyRebecca J Brown, David Araujo-Vilar, Kelly J Walkovich, et al.
Lipids in Health and Disease|December 6, 2021
Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept studyMaria C Foss-Freitas, Baris Akinci, Adam Neidert, et al.
Hospital Practice (1995)|September 26, 2014
Impact of left ventricular assist device on diabetes management: an evaluation through case analysis and clinical impactAngela R Subauste, Nazanene H Esfandiari, Yunyan Qu, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2004
Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiencyJennifer R McDuffie, Patti A Riggs, Karim A Calis, et al.
Endocrinology, Diabetes & Metabolism Case Reports|March 28, 2020
The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotideBaris Akinci, Rasimcan Meral, Diana Rus, et al.
Endocrine|February 27, 2019
Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophyElif A Oral, Phillip Gorden, Elaine Cochran, et al.
Endocrine|April 13, 2018
Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophyRebecca J Brown, Elif A Oral, Elaine Cochran, et al.
Obesity (Silver Spring, Md.)|January 25, 2021
The Metabolic Equivalent BMI in Patients with Familial Partial Lipodystrophy (FPLD) Compared with Those with Severe ObesityEden Koo, Maria C Foss-Freitas, Rasimcan Meral, et al.
Gastroenterology|January 26, 2018
Lamin A/C Maintains Exocrine Pancreas Homeostasis by Regulating Stability of RB and Activity of E2FJared S Elenbaas, Juliana Bragazzi Cunha, Rodrigo Azuero-Dajud, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Clinical Endocrinology|November 22, 2015
Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophyJean L Chan, Joy Koda, Joseph S Heilig, et al.
Frontiers in Endocrinology|June 5, 2025
A real-world pharmacovigilance assessment and literature review of lymphoma development in lipodystrophyRebecca J Brown, David Araujo-Vilar, Kelly J Walkovich, et al.
Lipids in Health and Disease|December 6, 2021
Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept studyMaria C Foss-Freitas, Baris Akinci, Adam Neidert, et al.
Hospital Practice (1995)|September 26, 2014
Impact of left ventricular assist device on diabetes management: an evaluation through case analysis and clinical impactAngela R Subauste, Nazanene H Esfandiari, Yunyan Qu, et al.
The Journal of Clinical Endocrinology and Metabolism|September 10, 2004
Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiencyJennifer R McDuffie, Patti A Riggs, Karim A Calis, et al.
Endocrinology, Diabetes & Metabolism Case Reports|March 28, 2020
The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotideBaris Akinci, Rasimcan Meral, Diana Rus, et al.
Endocrine|February 27, 2019
Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophyElif A Oral, Phillip Gorden, Elaine Cochran, et al.
Endocrine|April 13, 2018
Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophyRebecca J Brown, Elif A Oral, Elaine Cochran, et al.
Obesity (Silver Spring, Md.)|January 25, 2021
The Metabolic Equivalent BMI in Patients with Familial Partial Lipodystrophy (FPLD) Compared with Those with Severe ObesityEden Koo, Maria C Foss-Freitas, Rasimcan Meral, et al.
Gastroenterology|January 26, 2018
Lamin A/C Maintains Exocrine Pancreas Homeostasis by Regulating Stability of RB and Activity of E2FJared S Elenbaas, Juliana Bragazzi Cunha, Rodrigo Azuero-Dajud, et al.
Pageof 8